Sequenom, Inc.  

(Public, NASDAQ:SQNM)   Watch this stock  
Find more results for SQNM
+0.15 (4.24%)
Mar 3 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.50 - 3.75
52 week 2.25 - 4.19
Open 3.50
Vol / Avg. 1.59M/916,950.00
Mkt cap 414.34M
P/E     -
Div/yield     -
EPS -0.42
Shares 117.36M
Beta 0.41
Inst. own 57%
Mar 4, 2015
Q4 2014 Sequenom Inc Earnings Call - 5:00PM EST - Add to calendar
Mar 4, 2015
Q4 2014 Sequenom Inc Earnings Release - 4:00PM EST - Add to calendar
Jan 15, 2015
Sequenom Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -16.02% -66.13%
Operating margin -15.92% -60.59%
EBITD margin - -47.56%
Return on average assets -18.32% -54.57%
Return on average equity - -14282.71%
Employees 570 -
CDP Score - -


3595 John Hopkins Court
SAN DIEGO, CA 92121-1331
United States - Map
+1-858-2029000 (Phone)
+1-858-2029001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Sequenom, Inc. (Sequenom) is a molecular diagnostic testing and genetics analysis company. The Company provides genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. Sequenom is engaged in researching, developing, and pursuing the commercialization of various noninvasive molecular diagnostic tests for prenatal genetic disorders, and diseases, women�s health-related disorders and diseases, ophthalmology, and other medical conditions such as oncology, infectious diseases, and autoimmunity. The Company conducts its business through two operating segments, Sequenom Laboratories and Sequenom Bioscience. The laboratories offer MaterniT21 PLUS test, the HerediT CF test, and the SensiGene RHD test. Sequenom bioscience manufactures and sells MassARRAY System, which provides quantitative DNA methylation analysis and comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control.

Officers and directors

Harry F. Hixson Jr., Ph.D. Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
William J. Welch President, Chief Executive Officer, Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Carolyn D. Beaver Chief Financial Officer, Chief Accounting Officer, Vice President
Age: 56
Bio & Compensation  - Reuters
R. William Bowen Senior Vice President, General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Michael Monko Senior Vice President - Bioscience
Age: 54
Bio & Compensation  - Reuters
Robin G. Weiner Senior Vice President - Quality and Regulatory Affairs
Age: 58
Bio & Compensation  - Reuters
Dirk van den Boom Ph.D. Chief Scientific & Strategy Officer
Age: 43
Bio & Compensation  - Reuters
Richard A. Lerner M.D. Lead Independent Director
Age: 76
Bio & Compensation  - Reuters
Myla P. Lai-Goldman M.D. Director
Age: 56
Bio & Compensation  - Reuters
Ronald M. Lindsay Ph.D. Director
Age: 66
Bio & Compensation  - Reuters